Equities research analysts expect that ChromaDex Co. (NASDAQ:CDXC – Get Rating) will announce earnings per share of ($0.09) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for ChromaDex’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.12). ChromaDex reported earnings per […]
Zacks Investment Research downgraded shares of ChromaDex (NASDAQ:CDXC – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Monday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, […]
ChromaDex (NASDAQ:CDXC – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and […]
Wall Street brokerages expect ChromaDex Co. (NASDAQ:CDXC – Get Rating) to report $17.42 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for ChromaDex’s earnings, with the lowest sales estimate coming in at $15.73 million and the highest estimate coming in at $19.00 million. ChromaDex posted sales of $14.68 […]
ChromaDex (NASDAQ:CDXC – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, […]